EZH2 and non-small cell lung carcinoma: Higher inflammatory markers are associated with unsatisfactory prognoses in NSCLC patients, according to a paper we just published [60]; these results imply that the effects of EZH2 on lung adenocarcinoma may be tightly linked to inflammatory factors.